Search

Your search keyword '"Cordier, J."' showing total 169 results
Start Over Author "Cordier, J." Search Limiters Available in Library Collection
169 results on '"Cordier, J."'

1. Progress and challenges of the ITER TBM Program from the IO perspective

Author

Giancarli, L.M., Barabash, V., Campbell, D.J., Chiocchio, S., Cordier, J.-J., Dammann, A., Dell’Orco, G., Elbez-Uzan, J., Fourneron, J.M., Friconneau, J.P., Gasparotto, M., Iseli, M., Jung, C.-Y., Kim, B.-Y., Lazarov, D., Levesy, B., Loughlin, M., Merola, M., Nevière, J.-C., Pascal, R., Ring, W., Schneiderova, I., Willms, S., Siarras, A., Shu, W., Snipes, J.A., and van der Laan, J.G.

Published
2016
Full Text
View/download PDF

4. Design finalization and start of construction of ITER vacuum vessel

Author

Ioki, K., Barabash, V., Choi, C.H., Cordier, J.-J., Daly, E., Dani, S., Davis, J., Giraud, B., Gribov, Y., Heitzenroeder, Ph., Hamlyn-Harris, C., Johnson, G., Jones, L., Jun, C., Kim, B.C., Kuzmin, E., Le Barbier, R., Loesser, D., Martinez, J.-M., Merola, M., Pathak, H., Preble, J., Reich, J., Sa, J.W., Terasawa, A., Utin, Yu., Wang, X., and Wu, S.

Published
2011
Full Text
View/download PDF

5. Long-Term Outcomes Among Participants in the WEGENT Trial of Remission-Maintenance Therapy for Granulomatosis With Polyangiitis (Wegenerʼs) or Microscopic Polyangiitis

Author

Puéchal, Xavier, Pagnoux, Christian, Perrodeau, Élodie, Hamidou, Mohamed, Boffa, Jean-Jacques, Kyndt, Xavier, Lifermann, François, Papo, Thomas, Merrien, Dominique, Smail, Amar, Delaval, Philippe, Hanrotel-Saliou, Catherine, Imbert, Bernard, Khouatra, Chahéra, Lambert, Marc, Leské, Charles, Ly, Kim H., Pertuiset, Edouard, Roblot, Pascal, Ruivard, Marc, Subra, Jean-François, Viallard, Jean-François, Terrier, Benjamin, Cohen, Pascal, Mouthon, Luc, Le Jeunne, Claire, Ravaud, Philippe, Guillevin, Loïc, Rispal, P., Baidi, N., Chrétien, O., Cevallos, R., Ducroix, J.-P., Darmaillacq, J.-G., Dubas, F., Maghakian, M.-N., Moreau, C., Dubos-Arvis, C., Frognier, R., Gobert, P., Pollini, J., Pingat, D., Janin-Manificat, L., Lafon, B., Kettaneh, A., Moiton, M., Ragnaud, J. M., Boudray, C., Raphanel, B., Renand, J.-P., Roux, M., Bonnaire, G., Guiso, A., André, J. M., Perrichot, R., Louvet, J., Artigues, N., Bienvenu, B., de Ligny, Hurault B., Le Hello, C., Letellier, P., Lobbedez, T., Ollivier, Y., Pujo, M., Ryckelynck, J.-P., Montseny, J.-J., Collet, P., Ayach, B., Dion, J.-J., Mouawad, H., Damade, R., Dupouët, L., Asgaraly, K., Depernet, B., Colin, T., Ioos, V., Rieu, V., Belmatoug, N., Foulon, L., Jebrak, G., du Coedic, L., Bachmeyer, C., Dumoulin, A., Godeau, B., Khellaf, M., Michel, M., Pastural, M., Schaeffer, A., Geffroy, M., Bielefeld, P., Fichet, D., Saraux, J.-L., Vinzio, S., Ehrlacher, P., Azria, A., Mariette, X., Tiab, M., Delansorne, D., Boullanger, N., Closs-Prophette, F., Goldstein, A., Bouscaud, L., Meunier, V., Hachulla, E., Hatron, P.-Y., Launay, D., Hottelart, C., Liozon, E., Longuet, O., Loustaud-Ratti, V., Soria, P., Vidal, E., Geffray, L., Henri, P., Landru, I., Guillemot, J.-M., Le Noach, J., Cordier, J.-F., Cottin, V., Gentil, B., Demolombe-Rague, S., Girard-Madoux, M.-H., Ninet, J., Pinède, L., Meynieux, J.-P., Serratrice, J., Xeridat, B., Bagnères, D., Roudier, J., Denis, B., Boillet, N., Geraads, A., Teyssandier, R., Degraeve, F., Le Quellec, A., Rivière, S., Rogé, C., Fauchay, J.-P., Wahl, D., Agard, C., Généreau, T., Meker, D., Bensakel, S., Vecina, F., Aubier, M., Foulon, G., Lelièvre, P., Lidove, O., Mignon, F., Meyer, O., Piperaud, M., Queffeulou, G., Vrtovsnik, F., Aouba, A., Arène, J.-P., Bérezné, A., Le Guern, V., Amoura, Z., Benveniste, O., Dimitri, D., Huong, Lê Thi D., Bergeron, A., Bourgarit, A., Farge, D., Mahr, A., Martinez, F., Séréni, D., Aslangul, E., Arnal, C., Cadranel, J., Daugas, E., Pelle, G., Rossert, J., Wislez, M., Gayraud, M., Bruet, A., Hillion, Y., Paccalin, M., Léone, J., Pennaforte, J.-L., Barbier, S., Legallicier, B., Dominique, S., Charasse, C., Coëtmeur, D., Duhamel, E., Goulias, J.-P., Bournerias, F., Gautherie, P., Schlienger, J.-L., Vidal, A., Diot, E., Diot, P., Vanhille, P., Bindi, P., and Cervantes, G.

Published
2016
Full Text
View/download PDF

6. ITER vacuum vessel design and construction

Author

Ioki, K., Barabash, V., Bachmann, C., Chappuis, P., Choi, C.H., Cordier, J.-J., Giraud, B., Gribov, Y., Heitzenroeder, Ph., Johnson, G., Jones, L., Jun, C., Kim, B.C., Kuzmin, E., Loesser, D., Martin, A., Martinez, J.-M., Merola, M., Pathak, H., Readman, P., Sugihara, M., Terasawa, A., Utin, Yu., Wang, X., and Wu, S.

Published
2010
Full Text
View/download PDF

12. Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss). A study of 157 patients by the Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires and the European Respiratory Society Taskforce on eosinophilic granulomatosis with polyangiitis (Churg-Strauss)

Author

Cottin, V, Bel, E, Bottero, P, Dalhoff, K, Humbert, M, Lazor, R, Sinico, R, Sivasothy, P, Wechsler, M, Groh, M, Marchand Adam, S, Khouatra, C, Wallaert, B, Taillé, C, Delaval, P, Cadranel, J, Bonniaud, P, Prévot, G, Hirschi, S, Gondouin, A, Dunogué, B, Chatté, G, Briault, C, Pagnoux, C, Jayne, D, Guillevin, L, Cordier, J, Sinico, Ra, Cordier, J., Cottin, V, Bel, E, Bottero, P, Dalhoff, K, Humbert, M, Lazor, R, Sinico, R, Sivasothy, P, Wechsler, M, Groh, M, Marchand Adam, S, Khouatra, C, Wallaert, B, Taillé, C, Delaval, P, Cadranel, J, Bonniaud, P, Prévot, G, Hirschi, S, Gondouin, A, Dunogué, B, Chatté, G, Briault, C, Pagnoux, C, Jayne, D, Guillevin, L, Cordier, J, Sinico, Ra, and Cordier, J.

Abstract

Objective: To guide nosology and classification of patients with eosinophilic granulomatosis with polyangiitis (EGPA) based on phenotype and presence or absence of ANCA. Methods: Organ manifestations and ANCA status were retrospectively analyzed based on the presence or not of predefined definite vasculitis features or surrogates of vasculitis in patients asthma, eosinophilia, and at least one systemic organ manifestation attributable to systemic disease. Results: The study population included 157 patients (mean age 49.4. ±. 14.1), with a follow-up of 7.4. ±. 6.4. years. Patients with ANCA (31%) more frequently had weight loss, myalgias, arthralgias, biopsy-proven vasculitis, glomerulonephritis on biopsy, hematuria, leukocytoclastic capillaritis and/or eosinophilic infiltration of arterial wall on biopsy, and other renal disease. A total of 41% of patients had definite vasculitis manifestations (37%) or strong surrogates of vasculitis (4%), of whom only 53% had ANCA. Mononeuritis multiplex was associated with systemic vasculitis (p. =0.005) and with the presence of ANCA (p. <. 0.001). Overall, 59% of patients had . polyangiitis as defined by definite vasculitis, strong surrogate of vasculitis, mononeuritis multiplex, and/or ANCA with at least one systemic manifestation other than ENT or respiratory. Patients with . polyangiitis had more systemic manifestations including arthralgias (p. =0.02) and renal disease (p. =0.024), had higher peripheral eosinophilia (p. =0.027), and a trend towards less myocarditis (p. =0.057). Using predefined criteria of vasculitis and surrogates of vasculitis, ANCA alone were found to be insufficient to categorise patients with vasculitis features. Conclusion: We suggest a revised nomenclature and definition for EGPA and a new proposed entity referred to as hypereosinophilic asthma with systemic (non vasculitic) manifestations

Published
2017

14. Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)

Author

Cottin, V, Bel, E, Bottero, P, Dalhoff, K, Humbert, M, Lazor, R, Sinico, R, Sivasothy, P, Wechsler, M, Groh, M, Marchand Adam, S, Khouatra, C, Wallaert, B, Taillé, C, Delaval, P, Cadranel, J, Bonniaud, P, Prévot, G, Hirschi, S, Gondouin, A, Dunogué, B, Chatté, G, Briault, A, Jayne, D, Guillevin, L, Cordier, J, Cordier, J., SINICO, RENATO ALBERTO, Cottin, V, Bel, E, Bottero, P, Dalhoff, K, Humbert, M, Lazor, R, Sinico, R, Sivasothy, P, Wechsler, M, Groh, M, Marchand Adam, S, Khouatra, C, Wallaert, B, Taillé, C, Delaval, P, Cadranel, J, Bonniaud, P, Prévot, G, Hirschi, S, Gondouin, A, Dunogué, B, Chatté, G, Briault, A, Jayne, D, Guillevin, L, Cordier, J, Cordier, J., and SINICO, RENATO ALBERTO

Abstract

The respiratory manifestations of eosinophilic granulomatosis with polyangiitis (EGPA) have not been studied in detail. In this retrospective multicentre study, EGPA was defined by asthma, eosinophilia and at least one new onset extra-bronchopulmonary organ manifestation of disease. The study population included 157 patients (mean±SD age 49.4±14.1 years), with a mean±SD blood eosinophil count of 7.4±6.4×109 L-1 at diagnosis. There was a mean±SD of 11.8±18.2 years from the onset of asthma to the diagnosis of EGPA, of 1.4±8.4 years from the first onset of peripheral eosinophilia to the diagnosis of EGPA, and of 7.4±6.4 years from EGPA diagnosis to the final visit. Despite inhaled and oral corticosteroid treatment, the severity of asthma increased 3-6 months before the onset of the systemic manifestations. Asthma was severe in 57%, 48%, and 56% of patients at diagnosis, at 3 years, and at the final visit, respectively. Persistent airflow obstruction was present in 38%, 30%, and 46% at diagnosis, at 3 years, and at the final visit, respectively. In EGPA, asthma is severe, antedates systemic manifestations by a mean of 12 years, and progresses to long-term persistent airflow obstruction despite corticosteroids in a large proportion of patients, which affects long-term management and morbidity.

Published
2016

15. A 12-WEEK COMBINATION OF CLARITHROMYCIN AND PREDNISONE COMPARED TO A 24-WEEK PREDNISONE ALONE TREATMENT IN CRYPTOGENIC AND RADIATION-INDUCED ORGANIZING PNEUMONIA

Author

Petitpierre, N., Cottin, V., sylvain marchand-adam, Hirschi, S., Rigaud, D., Court-Fortune, I., Jouneau, S., Israël-Biet, D., Molard, A., Cordier, J. -F, Lazor, R., Centre Hospitalier Universitaire Vaudois [Lausanne] (CHUV), Service de Pneumologie [Hôpital Louis Pradel – CHU Lyon] (Centre de Référence des Maladies Pulmonaires Rares), CHU Lyon-Hôpital Louis Pradel [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), CHU Strasbourg, Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), Institut de recherche en santé, environnement et travail (Irset), Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Institut National de la Santé et de la Recherche Médicale (INSERM)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Université d'Angers (UA), CHU Pontchaillou [Rennes], Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), Université d'Angers (UA)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Hôpital Louis Pradel [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL)-CHU Lyon, Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), and Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )

Subjects
Original Article: Clinical Research, recurrence, glucocorticoids, cryptogenic organizing pneumonia, [SDV]Life Sciences [q-bio], treatment outcome, interstitial, clarithromycin, lung diseases
Abstract

Background: Some data suggest that anti-inflammatory macrolides may be effective to treat organizing pneumonia (OP) and prevent relapses, but no formal comparison with prednisone alone is available. To explore this issue, we retrospectively compared the efficacy of a 12-week combined regimen of clarithromycin and prednisone with a 24-week prednisone alone regimen in OP. Methods: A standard 12-week regimen of combined clarithromycin and prednisone was designed for the treatment of cryptogenic or radiation-induced OP, aiming at reducing the cumulated prednisone dose and the relapse rate. Its use was left to the discretion of the treating physicians, members of the Groupe d’Etudes et de Recherche sur les Maladies Orphelines Pulmonaires. Data were compared to a historical control group treated with a standard 24-week prednisone alone regimen. Results: 16 patients were treated with combined therapy and 21 with prednisone alone. Complete radiological remission was achieved in 63% of the combined therapy group and 81% of the prednisone alone group (p=0.38). Symptomatic relapses occurred in 81% of the combined therapy group, and 52% of the prednisone alone group (p=0.14). No side effect of clarithromycin was reported. Conclusions: In patients with cryptogenic or radiation-induced OP, a 12-week regimen of clarithromycin and prednisone showed no benefit on remission rate and relapse rate as compared to a 24-week prednisone only regimen. (Sarcoidosis Vasc Diffuse Lung Dis 2018; 35: 230-238)

Published
2018

16. S.4.1 N-terminal pro-brain natriuretic peptide levels predict incident pulmonary arterial hypertension in SSc

Author

Thakkar, V., Stevens, W., Prior, D., Byron, J., Patterson, K., Hissaria, P., Moore, O., Roddy, J., Zochling, J., Sahhar, J., Nash, P., Tymms, K., Youssef, P., Proudman, S., Nikpour, M., Launay, D., Sitbon, O., Cordier, J. F., Hachulla, E., Mouthon, L., Gressin, V., Rottat, L., Clerson, P., Simonneau, G., Humbert, M., Carreira, P., Carmona, L., Joven, B. E., Denton, C. P., Allanore, Y., Walker, U. A., Matucci-Cerinic, M., Muller-Ladner, U., Hsu, V., Cheng, Q., and Steen, V.

Abstract

Introduction. Pulmonary arterial hypertension (PAH) is a major cause of mortality in SSc. NT-proBNP may be a useful biomarker of prevalent PAH but its role in screening for incident PAH has not been evaluated. Methods. Patients recruited into the Australian Scleroderma Cohort Study undergo annual echocardiography, pulmonary function tests (PFTs), 6-min walk test (6MWT) and have serum NT-proBNP measured (ElecsysproBNP II). The diagnosis of PAH is based on Dana point criteria at right heart catheterization (RHC). Patients with LV dysfunction or eGFR 36 mmHg, (ii) FVC/DLCO% >1.6 and no significant ILD, (iii) DLCO 189.2 pg/ml had a likelihood ratio of 26.4 for presence of PAH (c-statistic = 0.9; sensitivity 85%; specificity 97%). An NT-proBNP level 189.2 pg/ml and

Published
2017

18. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity

Author

Cottin, V., Nunes, H., Brillet, P.-Y., Delaval, P., Devouassaoux, G., Tillie-Leblond, I., Israel-Biet, D., Court-Fortune, I., Valeyre, D., Cordier, J.-F., Carré, P., Chabot, F., Chatté, G., Coëtmeur, D., Crestani, B., Dalphin, J.C., Dietemann, A., Gentil, B., Humbert, M., Lacronique, J., Mairesse, M., Marchand, Eric, Reynaud-Gaubert, M., Rétrovirus et Pathologie Comparée (RPC), Institut National de la Recherche Agronomique (INRA)-École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Ecole Nationale Vétérinaire de Lyon (ENVL), Centre Hospitalier Universitaire de Lyon, Service de Pneumologie, Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Hôpital Avicenne [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Pontchaillou [Rennes], Centre Hospitalier Universitaire de Lille (CHU de Lille), Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), Hospices Civils de Lyon (HCL), UCL - MD/MINT - Département de médecine interne, and UCL - (MGD) Service de pneumologie

Subjects
Adult, Male, Pulmonary and Respiratory Medicine, Spirometry, medicine.medical_specialty, Hypertension, Pulmonary, [SDV]Life Sciences [q-bio], Interstitial lung disease, EMPHYSEMA, 030204 cardiovascular system & hematology, Pulmonary arterial hypertension, Pulmonary fibrosis, Pulmonary function testing, 03 medical and health sciences, FEV1/FVC ratio, 0302 clinical medicine, Internal medicine, medicine, Humans, PULMONARY ARTERIAL HYPERTENSION, Aged, Retrospective Studies, Aged, 80 and over, Emphysema, INTERSTITIAL LUNG DISEASE, Lung, medicine.diagnostic_test, business.industry, Smoking, Middle Aged, respiratory system, medicine.disease, Survival Analysis, Pulmonary hypertension, Combined pulmonary fibrosis and emphysema, Respiratory Function Tests, respiratory tract diseases, 3. Good health, Surgery, PULMONARY FIBROSIS, medicine.anatomical_structure, Pulmonary Emphysema, 030228 respiratory system, Cardiology, Female, Tomography, X-Ray Computed, business
Abstract

The syndrome resulting from combined pulmonary fibrosis and emphysema has not been comprehensively described. The current authors conducted a retrospective study of 61 patients with both emphysema of the upper zones and diffuse parenchymal lung disease with fibrosis of the lower zones of the lungs on chest computed tomography. Patients (all smokers) included 60 males and one female, with a mean age of 65 yrs. Dyspnoea on exertion was present in all patients. Basal crackles were found in 87% and finger clubbing in 43%. Pulmonary function tests were as follows (mean ± SD): total lung capacity 88% ± 17, forced vital capacity (FVC) 88% ± 18, forced expiratory volume in one second (FEV1) 80% ± 21 (% predicted), FEV1/FVC 69% ± 13, carbon monoxide diffusion capacity of the lung 37% ± 16 (% predicted), carbon monoxide transfer coefficient 46% ± 19. Pulmonary hypertension was present in 47% of patients at diagnosis, and 55% during follow-up. Patients were followed for a mean of 2.1 ± 2.8 yrs from diagnosis. Survival was 87.5% at 2 yrs and 54.6% at 5 yrs, with a median of 6.1 yrs. The presence of pulmonary hypertension at diagnosis was a critical determinant of prognosis. The authors hereby individualise the computer tomography-defined syndrome of combined pulmonary fibrosis and emphysema characterised by subnormal spirometry, severe impairment of gas exchange, high prevalence of pulmonary hypertension, and poor survival. Copyright©ERS Journals Ltd 2005.

Published
2005

19. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management

Author

Groh, M, Pagnoux, C, Baldini, C, Bel, E, Bottero, P, Cottin, V, Dalhoff, K, Dunogué, B, Gross, W, Holle, J, Humbert, M, Jayne, D, Jennette, J, Lazor, R, Mahr, A, Merkel, P, Mouthon, L, Sinico, R, Specks, U, Vaglio, A, Wechsler, M, Cordier, J, Guillevin, L, Guillevin, L., SINICO, RENATO ALBERTO, Groh, M, Pagnoux, C, Baldini, C, Bel, E, Bottero, P, Cottin, V, Dalhoff, K, Dunogué, B, Gross, W, Holle, J, Humbert, M, Jayne, D, Jennette, J, Lazor, R, Mahr, A, Merkel, P, Mouthon, L, Sinico, R, Specks, U, Vaglio, A, Wechsler, M, Cordier, J, Guillevin, L, Guillevin, L., and SINICO, RENATO ALBERTO

Abstract

Objective To develop disease-specific recommendations for the diagnosis and management of eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) (EGPA). Methods The EGPA Consensus Task Force experts comprised 8 pulmonologists, 6 internists, 4 rheumatologists, 3 nephrologists, 1 pathologist and 1 allergist from 5 European countries and the USA. Using a modified Delphi process, a list of 40 questions was elaborated by 2 members and sent to all participants prior to the meeting. Concurrently, an extensive literature search was undertaken with publications assigned with a level of evidence according to accepted criteria. Drafts of the recommendations were circulated for review to all members until final consensus was reached. Results Twenty-two recommendations concerning the diagnosis, initial evaluation, treatment and monitoring of EGPA patients were established. The relevant published information on EGPA, antineutrophil-cytoplasm antibody-associated vasculitides, hypereosinophilic syndromes and eosinophilic asthma supporting these recommendations was also reviewed. Discussion These recommendations aim to give physicians tools for effective and individual management of EGPA patients, and to provide guidance for further targeted research.

Published
2015

20. Projecting Different Identities: A Longitudinal Study of the “Whipsaw” Effects of Changing Leadership Discourse About the Triple Bottom Line

Author

Moingeon, Bertrand, Mirvis, P., Bayle-Cordier, J., Moingeon, Bertrand, Mirvis, P., and Bayle-Cordier, J.

Abstract

This paper focuses on changes in leadership’s discourse about the “triple bottom line” in Ben & Jerry’s ice cream from its founding days through to its acquisition by and integration into Unilever. For this study, we analyzed CEO claims about “who we are” from their letters in annual reports (what we label projected identity). A sample of employees (both long-service and relative newcomers) were interviewed about their perceptions of B&J’s over the thirty years covered. Findings reveal that successive CEO’s stressed different “logics” about the business and what would make it successful over the years with the founders emphasizing a strong linkage between the economic, product, and social components of the company’s triple bottom line and their next three successors decoupling these components and pushing, each in different ways, for stronger financial returns. As a result, organization members were “whipsawed” between their CEOs’ different logics and identity claims. The CEO letters exhibit a progression over time from a more normative to utilitarian tone familiar in the organizational identity literature. The messaging shifts, however, when a fifth CEO takes charge and re-integrates the firm’s triple bottom line. Thus the firm’s projected identity evolved in a U pattern starting with an integrated triple bottom line logic, shifting to a more linear logic where the economic mission dominates, and then reintegration where multiple bottom lines are embraced once again. Here we explore both the strategic (external) and personal (internal) challenges informing the different CEOs’ messages over years, the whipsaw effect on staff, and the longer term evolution of projected identity in the company and reemergence of its integrated triple bottom line. This study contributes to the CSR and organization identity literatures by documenting how CEO’s (and their company) must struggle with maintaining an integrated triple bottom line in the context of commercial challenges and

Published
2015

23. The rapid atmospheric monitoring system of the Pierre Auger Observatory

Author

Abreu, P., Aglietta, M, Ahlers, M., Ahn, M., Albuquerque, E. J., Allard, I. F. M., Allekotte, D., Allen, I., Allison, J., Almela, P., Castillo, A., Alvarez Muniz, J. A., Batista, J., Ambrosio, R. A., Aminaei, M., Anchordoqui, A., Andringa, L., Antici'C, S., Aramo, T., Arganda, C., Arqueros, E., Asorey, F., Assis, H., Aublin, P., Ave, J., Avenier, M., Avila, M., Badescu, G., Balzer, A. M., Barber, M., Barbosa, K. B., Bardenet, A. F., Barroso, R., Baughman, S. L. C., Bauml, B., Baus, J., Beatty, C., Becker, J. J., Belletoile, K. H., Bellido, A., Benzvi, J. A., Berat, S., Bertou, C., Biermann, X., Billoir, P. L., Blanco, P., Blanco, F., Bleve, M., Blumer, C., Bohacova, H., Boncioli, M., Bonifazi, D., Bonino, C., Borodai, R., Brack, N., Brancus, J., Brogueira, I., Brown, P., Bruijn, W. C., Buchholz, R., Bueno, P., Buroker, A., Burton, L., Caballero Mora, R. E., Caccianiga, K. S., Caramete, B., Caruso, L., Castellina, R., Catalano, A., Cataldi, O., Cazon, G., Cester, L., Chauvin, R., Cheng, J., Chiavassa, S. H., Chinellato, A., Diaz, J. A., Chudoba, J. C., Cilmo, J., Clay, M., Cocciolo, R. W., Collica, G., Coluccia, L., Conceicao, M. R., Contreras, R., Cook, F., Cooper, H., Coppens, M. J., Cordier, J., Coutu, A., Covault, S., Creusot, C. E., Criss, A., Cronin, A., Curutiu, J., Dagoret Campagne, A., Dallier, S., Daniel, R., Dasso, B., Daumiller, S., Dawson, K., de Almeida, B. R., De Domenico, R. M., De Donato, M., de Jong, C., De la Vega, S. J., de Mello, G., Neto, W. J. M., Mitri, Jrtd, de Souza, I., de Vries, V., del Peral, K. D., del Rio, L., Deligny, M., Dembinski, O., Dhital, H., Di Giulio, N., Castro, C., Diep, M. L. D., Diogo, P. N., Dobrigkeit, F., Docters, C., D'Olivo, W., Dong, J. C., Dorofeev, P. N., dos Anjos, A., Dova, J. C., D'Urso, M. T., Dutan, D., Ebr, I., Engel, J., Erdmann, R., Escobar, M., Espadanal, C. O., Etchegoyen, J., Luis, A., Falcke, P. F. S., Fang, H., Farrar, K., Fauth, G., Fazzini, A. C., Ferguson, N., Fick, A. P., Figueira, B., Filevich, J. M., Filipcic, A., Fliescher, A., Fracchiolla, S., Fraenkel, C. E., Fratu, E. D., Frohlich, O., Fuchs, U., Gaior, B., Gamarra, R., Gambetta, R. F., Garcia, S., Roca, B., Garcia Gamez, S. T. G., Garcia Pinto, D., Garilli, D., Bravo, G., Gemmeke, A. G., Ghia, H., Giller, P. L., Gitto, M., Glass, J., Gold, H., Golup, M. S., Albarracin, G., Berisso, F. G., Vitale, M. G., Goncalves, P. F. G., Gonzalez, P., Gookin, G., Gorgi, B., Gouffon, A., Grashorn, P., Grebe, E., Griffith, S., Grillo, N., Guardincerri, A. F., Guarino, Y., Guedes, F., Hansen, G. P., Harari, P., Harrison, D., Harton, T. A., Haungs, J. L., Hebbeker, A., Heck, T., Herve, D., Hojvat, A. E., Hollon, C., Holmes, N., Homola, V. C., Horandel, P., Horvath, J. R., Hrabovsky, P., Huber, M., Huege, D., Insolia, T., Ionita, A., Italiano, F., Jansen, A., Jarne, S., Jiraskova, C., Josebachuili, S., Kadija, M., Kampert, K., Karhan, K. H., Kasper, P., Katkov, P., Kegl, I., Keilhauer, B., Keivani, B., Kelley, A., Kemp, J. L., Kieckhafer, E., Klages, R. M., Kleifges, H. O., Kleinfeller, M., Knapp, J., Koang, J., Kotera, D. H., Krohm, K., Kromer, N., Kruppke Hansen, O., Kuempel, D., Kulbartz, D., Kunka, J. K., La Rosa, N., Lachaud, G., Lahurd, C., Latronico, D., Lauer, L., Lautridou, R., Le Coz, P., Leao, S., Lebrun, Msab and, Lebrun, D., de Oliveira, P., Letessier Selvon, M. A. L., Lhenry Yvon, A., Link, I., Lopez, K., Aguera, R., Louedec, A. L., Bahilo, K., J. L., Lu, Lucero, L., Ludwig, A., Lyberis, M., Maccarone, H., Macolino, M. C., Maldera, C., Maller, S., Mandat, J., Mantsch, D., Mariazzi, P., Marin, A. G., Marin, J., Maris, V., Falcon, I. C., Marsella, H. R. M., Martello, G., Martin, D., Martinez, L., Bravo, H., Martraire, O. M., Meza, D., Mathes, J. J. M., Matthews, H. J., Matthews, J., Matthiae, A. J., Maurel, G., Maurizio, D., Mazur, D., Medina Tanco, P. O., Melissas, G., Melo, M., Menichetti, D., Menshikov, E., Mertsch, A., Meurer, P., Meyhandan, C., Mi'Canovi'C, R., Micheletti, S., Minaya, M. I., Miramonti, I. A., Molina Bueno, L., Mollerach, L., Monasor, S., Ragaigne, M., Montanet, D. M., Morales, F., Morello, B., Moreno, C., Moreno, E., Mostafa, J. C., Moura, M., Muller, C. A., Muller, M. A., Munchmeyer, G., Mussa, M., Navarra, R., Navarro, G., Navas, J. L., Necesal, S., Nellen, P., Nelles, L., Neuser, A., Nhung, J., Niechciol, P. T., Niemietz, M., Nierstenhoefer, L., Nitz, N., Nosek, D., Nozka, D., Oehlschlager, L., Olinto, J., Ortiz, A., Pacheco, M., Selmi Dei, N., Palatka, D. P., Pallotta, M., Palmieri, J., Parente, N., Parizot, G., Parra, E., Pastor, A., Paul, S., Pech, T., Pekala, M., Pelayo, J., Pepe, R., Perrone, I. M., Pesce, L., Petermann, R., Petrera, E., Petrolini, Alessandro, Petrov, A., Pfendner, Y., Piegaia, C., Pierog, R., Pieroni, T., Pimenta, P., Pirronello, M., Platino, V., Plum, M., Ponce, M., Pontz, V. H., Porcelli, M., Privitera, A., Prouza, P., Quel, M., Querchfeld, E. J., Rautenberg, S., Ravel, J., Ravignani, O., Revenu, D., Ridky, B., Riggi, J., Risse, S., Ristori, M., Rivera, P., Rizi, H., Roberts, V., de Carvalho, J., Rodriguez, W. R., Cabo, G., Martino, I. R., Rojo, J. R., Rodriguez Frias, J. R., Ros, M. D., Rosado, G., Rossler, J., Roth, T., Rouille d'Orfeuil, M., Roulet, B., Rovero, E., Ruhle, A. C., Saftoiu, C., Salamida, A., Salazar, F., Greus, H., Salina, F. S., Sanchez, G., Santo, F., Santos, C. E., Santos, E., Sarazin, E. M., Sarkar, F., Sarkar, B., Sato, S., Scharf, R., Scherini, N., Schieler, V., Schiffer, H., Schmidt, P., Scholten, A., Schoorlemmer, O., Schovancova, H., Schovanek, J., Schroder, P., Schulte, F., Schuster, S., Sciutto, D., Scuderi, S. J., Segreto, M., Settimo, A., Shadkam, M., Shellard, A., Sidelnik, R. C., Sigl, I., Lopez, G., Sima, H. H. S., Smialkowski, O., Smida, A., Snow, R., Sommers, G. R., Sorokin, P., Spinka, J., Squartini, H., Srivastava, R., Stanic, Y. N., Stapleton, S., Stasielak, J., Stephan, J., Stutz, M., Suarez, A., Suomijarvi, F., Supanitsky, T., Susa, A. D., Sutherland, T., Swain, M. S., Szadkowski, J., Szuba, Z., Tapia, M., Tartare, A., Tascau, M., Tcaciuc, O., Thao, R., Thomas, N. T., Tiffenberg, D., Timmermans, J., Tkaczyk, C., Peixoto, W., Toma, C. J. T., Tomankova, G., Tome, L., Tonachini, B., Travnicek, A., Tridapalli, P., Tristram, D. B., Trovato, G., Tueros, E., Ulrich, M., Unger, R., Urban, M., Galicia, M., Valino, J. F. V., Valore, I., Van Aar, L., van den Berg, G., van Vliet, A. M., Varela, A., Cardenas, E., Vazquez, B. V., Vazquez, J. R., Veberic, R. A., Verzi, D., Vicha, V., Videla, J., Villasenor, M., Wahlberg, L., Wahrlich, H., Wainberg, P., Walz, O., Watson, D., Weber, A. A., Weidenhaupt, M., Weindl, K., Werner, A., Westerhoff, F., Whelan, S., Widom, B. J., Wieczorek, A., Wiencke, G., Wilczynska, L., Wilczynski, B., Will, H., Williams, M., Winchen, C., Wommer, T., Wundheiler, M., Yamamoto, B., Yapici, T., Younk, T., Yuan, P., Yushkov, G., Garcia, A., Zas, B. Z., Zavrtanik, E., Zavrtanik, D., Zaw, M., Zepeda, I., Zhou, A., Zhu, J., Silva, Y., Ziolkowski, M. Z., Pierre Auger, M., APC - Astrophysique des Hautes Energies (APC - AHE), AstroParticule et Cosmologie (APC (UMR_7164)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Observatoire de Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Observatoire de Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS)-Alma Mater Studiorum Università di Bologna [Bologna] (UNIBO), Laboratoire de Physique Subatomique et de Cosmologie (LPSC), Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Institut Polytechnique de Grenoble - Grenoble Institute of Technology-Centre National de la Recherche Scientifique (CNRS), Laboratoire de l'Accélérateur Linéaire (LAL), Université Paris-Sud - Paris 11 (UP11)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), Laboratoire SUBATECH Nantes (SUBATECH), Mines Nantes (Mines Nantes)-Université de Nantes (UN)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), Institut de Physique Nucléaire d'Orsay (IPNO), PIERRE AUGER, P., Abreu, M., Aglietta, M., Ahler, E. J., Ahn, I. F. M., Albuquerque, D., Allard, I., Allekotte, J., Allen, P., Allison, A., Almela, J., Alvarez Castillo, J., Alvarez Muñiz, R., Alves Batista, M., Ambrosio, A., Aminaei, L., Anchordoqui, S., Andringa, T., Antičić, C., Aramo, E., Arganda, F., Arquero, H., Asorey, P., Assi, J., Aublin, M., Ave, M., Avenier, G., Avila, A. M., Badescu, M., Balzer, K. B., Barber, A. F., Barbosa, R., Bardenet, S. L. C., Barroso, B., Baughman f, J., Bäuml, C., Bau, J. J., Beatty, K. H., Becker, A., Bellétoile, J. A., Bellido, S., Benzvi, C., Berat, X., Bertou, P. L., Biermann, P., Billoir, F., Blanco, M., Blanco, C., Bleve, H., Blümer, M., Boháčová, D., Boncioli, C., Bonifazi, R., Bonino, N., Borodai, J., Brack, I., Brancu, P., Brogueira, W. C., Brown, R., Bruijn i, P., Buchholz, A., Bueno, L., Buroker, R. E., Burton, K. S., Caballero Mora, B., Caccianiga, L., Caramete, R., Caruso, A., Castellina, O., Catalano, G., Cataldi, L., Cazon, R., Cester, J., Chauvin, S. H., Cheng, A., Chiavassa, J. A., Chinellato, J., Chirinos Diaz, J., Chudoba, M., Cilmo, R. W., Clay, Cocciolo, Giuseppe, L., Collica, Coluccia, MARIA RITA, R., Conceição, F., Contrera, H., Cook, M. J., Cooper, J., Coppen, A., Cordier, S., Coutu, C. E., Covault, A., Creusot, A., Cri, J., Cronin, A., Curutiu, S., Dagoret Campagne, R., Dallier, B., Daniel, S., Dasso, K., Daumiller, B. R., Dawson, R. M., de Almeida, M., De Domenico, C., De Donato, S. J., de Jong, G., De La Vega, W. J. M., de Mello Junior, J. R. T., de Mello Neto, DE MITRI, Ivan, V., de Souza, K. D., de Vrie, L., del Peral, M., del Río, O., Deligny, H., Dembinski, N., Dhital, C., Di Giulio, M. L., Díaz Castro, P. N., Diep, F., Diogo, C., Dobrigkeit, W., Docter, J. C., D'Olivo, P. N., Dong, A., Dorofeev, J. C., dos Anjo, M. T., Dova, D., D'Urso, I., Dutan, J., Ebr, R., Engel, M., Erdmann, C. O., Escobar, J., Espadanal, A., Etchegoyen, P., Facal San Lui, H., Falcke, K., Fang, G., Farrar, A. C., Fauth, N., Fazzini, A. P., Ferguson, B., Fick, J. M., Figueira, A., Filevich, A., Filipčič, S., Fliescher, C. E., Fracchiolla, E. D., Fraenkel!, O., Fratu, U., Fröhlich, B., Fuch, R., Gaior, R. F., Gamarra, S., Gambetta, B., García, S. T., Garcia Roca, D., Garcia Gamez, D., Garcia Pinto, G., Garilli, A., Gascon Bravo, H., Gemmeke, P. L., Ghia, M., Giller, J., Gitto, H., Gla, M. S., Gold, G., Golup, F., Gomez Albarracin, M., Gómez Berisso, P. F., Gómez Vitale, P., Gonçalve, J. G., Gonzalez, B., Gookin, A., Gorgi, P., Gouffon, E., Grashorn, S., Grebe, N., Griffith, A. F., Grillo, Y., Guardincerri, F., Guarino, G. P., Guede, P., Hansen, D., Harari, T. A., Harrison, J. L., Harton, A., Haung, T., Hebbeker, D., Heck, A. E., Herve, C., Hojvat, N., Hollon, V. C., Holme, P., Homola, J. R., Hörandel, P., Horvath, M., Hrabovský, D., Huber, T., Huege, A., Insolia, F., Ionita, A., Italiano, S., Jansen, C., Jarne, S., Jiraskova, M., Josebachuili, K., Kadija, K. H., Kampert, P., Karhan, P., Kasper, I., Katkov, B., Kégl, B., Keilhauer, A., Keivani, J. L., Kelley, E., Kemp, R. M., Kieckhafer, H. O., Klage, M., Kleifge, J., Kleinfeller, J., Knapp, D. H., Koang, K., Kotera, N., Krohm, O., Krömer, D., Kruppke Hansen, D., Kuempel, J. K., Kulbartz, N., Kunka, G., La Rosa, C., Lachaud, D., Lahurd, L., Latronico, R., Lauer, P., Lautridou, S., Le Coz, M. S. A. B., Leão, D., Lebrun, P., Lebrun, M. A., Leigui de Oliveira, A., Letessier Selvon, I., Lhenry Yvon, K., Link, R., López, A., Lopez Agüera, K., Louedec, J., Lozano Bahilo, L., Lu, A., Lucero, M., Ludwig, H., Lyberi, M. C., Maccarone, C., Macolino, S., Maldera, J., Maller, D., Mandat, P., Mantsch, A. G., Mariazzi, J., Marin, V., Marin, I. C., Mari, H. R., Marquez Falcon, Marsella, Giovanni, Martello, Daniele, L., Martin, H., Martinez, O., Martínez Bravo, D., Martraire, J. J., Masías Meza, H. J., Mathe, J., Matthew, J. A. J., Matthew, G., Matthiae, D., Maurel, D., Maurizio, P. O., Mazur, G., Medina Tanco, M., Melissa, D., Melo, E., Menichetti, A., Menshikov, P., Mertsch, C., Meurer, R., Meyhandan, S., Mićanović, M. I., Micheletti, I. A., Minaya, L., Miramonti, L., Molina Bueno, S., Mollerach, M., Monasor, D., Monnier Ragaigne, F., Montanet, B., Morale, C., Morello, E., Moreno, J. C., Moreno, M., Mostafá, C. A., Moura, M. A., Muller, G., Müller, M., Münchmeyer, R., Mussa, G., Navarra ‡, J. L., Navarro, S., Nava, P., Necesal, L., Nellen, A., Nelle, J., Neuser, P. T., Nhung, M., Niechciol, L., Niemietz, N., Nierstenhoefer, D., Nitz, D., Nosek, L., Nožka, J., Oehlschläger, A., Olinto, M., Ortiz, N., Pacheco, D., Pakk Selmi Dei, M., Palatka, J., Pallotta, N., Palmieri, G., Parente, E., Parizot, A., Parra, S., Pastor, T., Paul, M., Pech, J., Pękala, R., Pelayo, I. M., Pepe, Perrone, Lorenzo, R., Pesce, E., Petermann, S., Petrera, A., Petrolini, Y., Petrov, C., Pfendner, R., Piegaia, T., Pierog, P., Pieroni, M., Pimenta, V., Pirronello, M., Platino, M., Plum, V. H., Ponce, M., Pontz, A., Porcelli, P., Privitera, M., Prouza, E. J., Quel, S., Querchfeld, J., Rautenberg, O., Ravel, D., Ravignani, B., Revenu, J., Ridky, S., Riggi, M., Risse, P., Ristori, H., Rivera, V., Rizi, J., Robert, W., Rodrigues de Carvalho, G., Rodriguez, I., Rodriguez Cabo, J., Rodriguez Martino, J., Rodriguez Rojo, M. D., Rodríguez Fría, G., Ro, J., Rosado, T., Rossler, M., Roth, B., Rouillé d'Orfeuil, E., Roulet, A. C., Rovero, C., Rühle, A., Saftoiu, F., Salamida, H., Salazar, F., Salesa Greu, G., Salina, F., SÃ! ¡nchez, C. E., Santo, E., Santo, E. M., Santo, F., Sarazin, B., Sarkar, S., Sarkar, R., Sato, N., Scharf, V., Scherini, H., Schieler, P., Schiffer, A., Schmidt, O., Scholten, H., Schoorlemmer, J., Schovancova, P., Schovánek, F., Schröder, S., Schulte, D., Schuster, S. J., Sciutto, M., Scuderi, A., Segreto, M., Settimo, A., Shadkam, R. C., Shellard, I., Sidelnik, G., Sigl, H. H., Silva Lopez, O., Sima, A., Śmiałkowski, R., Šmída, G. R., Snow, P., Sommer, J., Sorokin, H., Spinka, R., Squartini, Y. N., Srivastava, S., Stanic, J., Stapleton, J., Stasielak, M., Stephan, A., Stutz, F., Suarez, T., Suomijärvi, A. D., Supanitsky, T., Šuša, M. S., Sutherland, J., Swain, Z., Szadkowski, M., Szuba, A., Tapia, M., Tartare, O., Taşcău, R., Tcaciuc, N. T., Thao, D., Thoma, J., Tiffenberg, C., Timmerman, W., Tkaczyk, C. J., Todero Peixoto, G., Toma, L., Tomankova, B., Tomé, A., Tonachini, P., Travnicek, D. B., Tridapalli, G., Tristram, E., Trovato, M., Tuero, R., Ulrich, M., Unger, M., Urban, J. F., Valdés Galicia, I., Valiño, L., Valore, G., van Aar, A. M., van den Berg, A., van Vliet, E., Varela, B., Vargas Cárdena, J. R., Vázquez, R. A., Vázquez, D., Veberič, V., Verzi, J., Vicha, M., Videla, L., Villaseñor, H., Wahlberg, P., Wahrlich, O., Wainberg, D., Walz, A. A., Watson, M., Weber, K., Weidenhaupt, A., Weindl, F., Werner, S., Westerhoff, B. J., Whelan, A., Widom, G., Wieczorek, L., Wiencke, B., Wilczyńska, H., Wilczyński, M., Will, C., William, T., Winchen, M., Wommer, B., Wundheiler, T., Yamamoto a, T., Yapici, P., Younk, G., Yuan, A., Yushkov, B., Zamorano Garcia, E., Za, D., Zavrtanik, M., Zavrtanik, I., Zaw h, A., Zepeda b, J., Zhou, Y., Zhu, M., Zimbres Silva, M. Ziolkowski, ., P. Abreu, M. Aglietta, M. Ahler, E.J. Ahn, I.F.M. Albuquerque, D. Allard, I. Allekotte, J. Allen, P. Allison, A. Almela, J. Alvarez Castillo, J. Alvarez-Muñiz, R. Alves Batista, M. Ambrosio, A. Aminaei, L. Anchordoqui, S. Andringa, T. Antičić, C. Aramo, E. Arganda, F. Arquero, H. Asorey, P. Assi, J. Aublin, M. Ave, M. Avenier, G. Avila, A.M. Badescu, M. Balzer, K.B. Barber, A.F. Barbosa, R. Bardenet, S.L.C. Barroso, B. Baughman f, J. Bäuml, C. Bau, J.J. Beatty, K.H. Becker, A. Bellétoile, J.A. Bellido, S. BenZvi, C. Berat, X. Bertou, P.L. Biermann, P. Billoir, F. Blanco, M. Blanco, C. Bleve, H. Blümer, M. Boháčová, D. Boncioli, C. Bonifazi, R. Bonino, N. Borodai, J. Brack, I. Brancu, P. Brogueira, W.C. Brown, R. Bruijn i, P. Buchholz, A. Bueno, L. Buroker, R.E. Burton, K.S. Caballero-Mora, B. Caccianiga, L. Caramete, R. Caruso, A. Castellina, O. Catalano, G. Cataldi, L. Cazon, R. Cester, J. Chauvin, S.H. Cheng, A. Chiavassa, J.A. Chinellato, J. Chirinos Diaz, J. Chudoba, M. Cilmo, R.W. Clay, G. Cocciolo, L. Collica, M.R. Coluccia, R. Conceição, F. Contrera, H. Cook, M.J. Cooper, J. Coppen, A. Cordier, S. Coutu, C.E. Covault, A. Creusot, A. Cri, J. Cronin, A. Curutiu, S. Dagoret-Campagne, R. Dallier, B. Daniel, S. Dasso, K. Daumiller, B.R. Dawson, R.M. de Almeida, M. De Domenico, C. De Donato, S.J. de Jong, G. De La Vega, W.J.M. de Mello Junior, J.R.T. de Mello Neto, I. De Mitri, V. de Souza, K.D. de Vrie, L. del Peral, M. del Río, O. Deligny, H. Dembinski, N. Dhital, C. Di Giulio, M.L. Díaz Castro, P.N. Diep, F. Diogo, C. Dobrigkeit, W. Docter, J.C. D'Olivo, P.N. Dong, A. Dorofeev, J.C. dos Anjo, M.T. Dova, D. D'Urso, I. Dutan, J. Ebr, R. Engel, M. Erdmann, C.O. Escobar, J. Espadanal, A. Etchegoyen, P. Facal San Lui, H. Falcke, K. Fang, G. Farrar, A.C. Fauth, N. Fazzini, A.P. Ferguson, B. Fick, J.M. Figueira, A. Filevich, A. Filipčič, S. Fliescher, C.E. Fracchiolla, E.D. Fraenkel!, O. Fratu, U. Fröhlich, B. Fuch, R. Gaior, R.F. Gamarra, S. Gambetta, B. García, S.T. Garcia Roca, D. Garcia-Gamez, D. Garcia-Pinto, G. Garilli, A. Gascon Bravo, H. Gemmeke, P.L. Ghia, M. Giller, J. Gitto, H. Gla, M.S. Gold, G. Golup, F. Gomez Albarracin, M. Gómez Berisso, P.F. Gómez Vitale, P. Gonçalve, J.G. Gonzalez, B. Gookin, A. Gorgi, P. Gouffon, E. Grashorn, S. Grebe, N. Griffith, A.F. Grillo, Y. Guardincerri, F. Guarino, G.P. Guede, P. Hansen, D. Harari, T.A. Harrison, J.L. Harton, A. Haung, T. Hebbeker, D. Heck, A.E. Herve, C. Hojvat, N. Hollon, V.C. Holme, P. Homola, J.R. Hörandel, P. Horvath, M. Hrabovský, D. Huber, T. Huege, A. Insolia, F. Ionita, A. Italiano, S. Jansen, C. Jarne, S. Jiraskova, M. Josebachuili, K. Kadija, K.H. Kampert, P. Karhan, P. Kasper, I. Katkov, B. Kégl, B. Keilhauer, A. Keivani, J.L. Kelley, E. Kemp, R.M. Kieckhafer, H.O. Klage, M. Kleifge, J. Kleinfeller, J. Knapp, D.-H. Koang, K. Kotera, N. Krohm, O. Krömer, D. Kruppke-Hansen, D. Kuempel, J.K. Kulbartz, N. Kunka, G. La Rosa, C. Lachaud, D. LaHurd, L. Latronico, R. Lauer, P. Lautridou, S. Le Coz, M.S.A.B. Leão, D. Lebrun, P. Lebrun, M.A. Leigui de Oliveira, A. Letessier-Selvon, I. Lhenry-Yvon, K. Link, R. López, A. Lopez Agüera, K. Louedec, J. Lozano Bahilo, L. Lu, A. Lucero, M. Ludwig, H. Lyberi, M.C. Maccarone, C. Macolino, S. Maldera, J. Maller, D. Mandat, P. Mantsch, A.G. Mariazzi, J. Marin, V. Marin, I.C. Mari, H.R. Marquez Falcon, G. Marsella, D. Martello, L. Martin, H. Martinez, O. Martínez Bravo, D. Martraire, J.J. Masías Meza, H.J. Mathe, J. Matthew, J.A.J. Matthew, G. Matthiae, D. Maurel, D. Maurizio, P.O. Mazur, G. Medina-Tanco, M. Melissa, D. Melo, E. Menichetti, A. Menshikov, P. Mertsch, C. Meurer, R. Meyhandan, S. Mićanović, M.I. Micheletti, I.A. Minaya, L. Miramonti, L. Molina-Bueno, S. Mollerach, M. Monasor, D. Monnier Ragaigne, F. Montanet, B. Morale, C. Morello, E. Moreno, J.C. Moreno, M. Mostafá, C.A. Moura, M.A. Muller, G. Müller, M. Münchmeyer, R. Mussa, G. Navarra ‡, J.L. Navarro, S. Nava, P. Necesal, L. Nellen, A. Nelle, J. Neuser, P.T. Nhung, M. Niechciol, L. Niemietz, N. Nierstenhoefer, D. Nitz, D. Nosek, L. Nožka, J. Oehlschläger, A. Olinto, M. Ortiz, N. Pacheco, D. Pakk Selmi-Dei, M. Palatka, J. Pallotta, N. Palmieri, G. Parente, E. Parizot, A. Parra, S. Pastor, T. Paul, M. Pech, J. Pękala, R. Pelayo, I.M. Pepe, L. Perrone, R. Pesce, E. Petermann, S. Petrera, A. Petrolini, Y. Petrov, C. Pfendner, R. Piegaia, T. Pierog, P. Pieroni, M. Pimenta, V. Pirronello, M. Platino, M. Plum, V.H. Ponce, M. Pontz, A. Porcelli, P. Privitera, M. Prouza, E.J. Quel, S. Querchfeld, J. Rautenberg, O. Ravel, D. Ravignani, B. Revenu, J. Ridky, S. Riggi, M. Risse, P. Ristori, H. Rivera, V. Rizi, J. Robert, W. Rodrigues de Carvalho, G. Rodriguez, I. Rodriguez Cabo, J. Rodriguez Martino, J. Rodriguez Rojo, M.D. Rodríguez-Fría, G. Ro, J. Rosado, T. Rossler, M. Roth, B. Rouillé-d'Orfeuil, E. Roulet, A.C. Rovero, C. Rühle, A. Saftoiu, F. Salamida, H. Salazar, F. Salesa Greu, G. Salina, F. SÃ! ¡nchez, C.E. Santo, E. Santo, E.M. Santo, F. Sarazin, B. Sarkar, S. Sarkar, R. Sato, N. Scharf, V. Scherini, H. Schieler, P. Schiffer, A. Schmidt, O. Scholten, H. Schoorlemmer, J. Schovancova, P. Schovánek, F. Schröder, S. Schulte, D. Schuster, S.J. Sciutto, M. Scuderi, A. Segreto, M. Settimo, A. Shadkam, R.C. Shellard, I. Sidelnik, G. Sigl, H.H. Silva Lopez, O. Sima, A. Śmiałkowski, R. Šmída, G.R. Snow, P. Sommer, J. Sorokin, H. Spinka, R. Squartini, Y.N. Srivastava, S. Stanic, J. Stapleton, J. Stasielak, M. Stephan, A. Stutz, F. Suarez, T. Suomijärvi, A.D. Supanitsky, T. Šuša, M.S. Sutherland, J. Swain, Z. Szadkowski, M. Szuba, A. Tapia, M. Tartare, O. Taşcău, R. Tcaciuc, N.T. Thao, D. Thoma, J. Tiffenberg, C. Timmerman, W. Tkaczyk, C.J. Todero Peixoto, G. Toma, L. Tomankova, B. Tomé, A. Tonachini, P. Travnicek, D.B. Tridapalli, G. Tristram, E. Trovato, M. Tuero, R. Ulrich, M. Unger, M. Urban, J.F. Valdés Galicia, I. Valiño, L. Valore, G. van Aar, A.M. van den Berg, A. van Vliet, E. Varela, B. Vargas Cárdena, J.R. Vázquez, R.A. Vázquez, D. Veberič, V. Verzi, J. Vicha, M. Videla, L. Villaseñor, H. Wahlberg, P. Wahrlich, O. Wainberg, D. Walz, A.A. Watson, M. Weber, K. Weidenhaupt, A. Weindl, F. Werner, S. Westerhoff, B.J. Whelan, A. Widom, G. Wieczorek, L. Wiencke, B. Wilczyńska, H. Wilczyński, M. Will, C. William, T. Winchen, M. Wommer, B. Wundheiler, T. Yamamoto a, T. Yapici, P. Younk, G. Yuan, A. Yushkov, B. Zamorano Garcia, E. Za, D. Zavrtanik, M. Zavrtanik, I. Zaw h, A. Zepeda b, J. Zhou, Y. Zhu, M. Zimbres Silva, M. Ziolkowski ., Observatoire de Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Observatoire de Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Dipartimento di Astronomia, Universita degli Studi di Bologna, Alma Mater Studiorum Università di Bologna [Bologna] (UNIBO)-Alma Mater Studiorum Università di Bologna [Bologna] (UNIBO), Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Institut Polytechnique de Grenoble - Grenoble Institute of Technology-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Joseph Fourier - Grenoble 1 (UJF)-Centre National de la Recherche Scientifique (CNRS), Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Paris-Sud - Paris 11 (UP11), Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université de Nantes (UN)-Mines Nantes (Mines Nantes), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3), Aramo, Carla, D'Urso, Domenico, Guarino, Fausto, Valore, Laura, The Pierre Auger, Collaboration, KVI - Center for Advanced Radiation Technology, Research unit Astroparticle Physics, Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Observatoire de Paris, PSL Research University (PSL)-PSL Research University (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Observatoire de Paris, PSL Research University (PSL)-PSL Research University (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Dipartimento di Astronomia, Universita degli Studi di Bologna, Università di Bologna [Bologna] (UNIBO)-Università di Bologna [Bologna] (UNIBO), Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Institut Polytechnique de Grenoble - Grenoble Institute of Technology-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA), and PSL Research University (PSL)-PSL Research University (PSL)-Université Paris Diderot - Paris 7 (UPD7)

Subjects
[PHYS.ASTR.HE]Physics [physics]/Astrophysics [astro-ph]/High Energy Astrophysical Phenomena [astro-ph.HE], Astronomy, FOS: Physical sciences, Cosmic ray, Real-time monitoring, 01 natural sciences, Large detector systems for particle and astroparticle physics, Real-time monitoring, Control and monitor systems online, Optical telescope, Observatory, 0103 physical sciences, SHOWERS, Large detector systems for particle and astroparticle physics, Control and monitor systems online, FLUORESCENCE, 010303 astronomy & astrophysics, Instrumentation, Instrumentation and Methods for Astrophysics (astro-ph.IM), DETECTOR, Mathematical Physics, Remote sensing, Event reconstruction, Pierre Auger Observatory, High Energy Astrophysical Phenomena (astro-ph.HE), 010308 nuclear & particles physics, [SDU.ASTR.HE]Sciences of the Universe [physics]/Astrophysics [astro-ph]/High Energy Astrophysical Phenomena [astro-ph.HE], Física, ENERGY-SPECTRUM, Monitoring program, Aerosol, ATMOSFERA (MONITORAMENTO), Air shower, Experimental High Energy Physics, Física nuclear, Astrophysics - Instrumentation and Methods for Astrophysics, Astrophysics - High Energy Astrophysical Phenomena
Abstract

The Pierre Auger Observatory is a facility built to detect air showers produced by cosmic rays above 1017 eV. During clear nights with a low illuminated moon fraction, the UV fluorescence light produced by air showers is recorded by optical telescopes at the Observatory. To correct the observations for variations in atmospheric conditions, atmospheric monitoring is performed at regular intervals ranging from several minutes (for cloud identification) to several hours (for aerosol conditions) to several days (for vertical profiles of temperature, pressure, and humidity). In 2009, the monitoring program was upgraded to allow for additional targeted measurements of atmospheric conditions shortly after the detection of air showers of special interest, e. g., showers produced by very high-energy cosmic rays or showers with atypical longitudinal profiles. The former events are of particular importance for the determination of the energy scale of the Observatory, and the latter are characteristic of unusual air shower physics or exotic primary particle types. The purpose of targeted (or "rapid") monitoring is to improve the resolution of the atmospheric measurements for such events. In this paper, we report on the implementation of the rapid monitoring program and its current status. The rapid monitoring data have been analyzed and applied to the reconstruction of air showers of high interest, and indicate that the air fluorescence measurements affected by clouds and aerosols are effectively corrected using measurements from the regular atmospheric monitoring program. We find that the rapid monitoring program has potential for supporting dedicated physics analyses beyond the standard event reconstruction.

Published
2012

24. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension

Author

Humbert, Marc, Sitbon, Olivier, Yaïci, A., Montani, D., O'Callaghan, D. S., Jaïs, X., Parent, F., Savale, L., Natali, D., Günther, S., Chaouat, A., Chabot, F., Cordier, J.-F., Habib, G., Gressin, V., Jing, Z.-C., Souza, R., Simonneau, Gerald, Frachon, Irène, Service de pneumologie [Béclère], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Antoine Béclère [Clamart], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de résonance magnétique biologique et médicale (CRMBM), Assistance Publique - Hôpitaux de Marseille (APHM)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Service de pneumologie et Réanimation Respiratoire, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre-DHU Thorax Innovation, Groupe d'Etude de la Thrombose de Bretagne Occidentale (GETBO), Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Université de Brest (UBO)-Université de Brest (UBO), Département de Médecine Interne et Pneumologie [Brest] (DMIP - Brest), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Centre National de la Recherche Scientifique (CNRS), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Brestois Santé Agro Matière (IBSAM), and Université de Brest (UBO)-Université de Brest (UBO)

Subjects
Pulmonary and Respiratory Medicine, Male, medicine.medical_specialty, Multivariate analysis, Hypertension, Pulmonary, [SDV]Life Sciences [q-bio], Physical exercise, 030204 cardiovascular system & hematology, MESH: Multivariate Analysis, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Risk Factors, MESH: Risk Factors, Internal medicine, medicine, Prevalence, Pulmonary Medicine, Humans, Familial Primary Pulmonary Hypertension, Risk factor, MESH: Cohort Studies, MESH: Pulmonary Medicine, MESH: Prevalence, Aged, MESH: Treatment Outcome, MESH: Aged, MESH: Humans, MESH: Middle Aged, MESH: Hypertension, Pulmonary, business.industry, Respiratory disease, Middle Aged, medicine.disease, Pulmonary hypertension, MESH: Male, 3. Good health, Surgery, medicine.anatomical_structure, Treatment Outcome, 030228 respiratory system, Cohort, Multivariate Analysis, Female, business, MESH: Female, Artery, Cohort study
Abstract

International audience; Pulmonary arterial hypertension (PAH) is a progressive, fatal disease. We studied 674 consecutive adult patients who were prospectively enrolled in the French PAH registry (121 incident and 553 prevalent cases). Two survival analyses were performed. First, the cohort of 674 patients was followed for 3 yrs after study entry and survival rates described. Then, we focused on the subset with incident idiopathic, familial and anorexigen-associated PAH (n = 56) combined with prevalent patients who were diagnosed

Published
2010

25. Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome

Author

Cottin, V., Le Pavec, J., Prévot, G., Mal, H., Humbert, M., Simonneau, G., Cordier, J.-F., Berezné, A., Coëtmeur, D., Danner-Boucher, I., Funke, D., Israel-Biet, D., Marchand, Eric, Mouthon, L., Rétrovirus et Pathologie Comparée (RPC), Institut National de la Recherche Agronomique (INRA)-École pratique des hautes études (EPHE)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Ecole Nationale Vétérinaire de Lyon (ENVL), Hôpital Louis Pradel, Service de Pneumologie, Centre de Référence National des Maladies Pulmonaires Rares, Hospices Civils de Lyon (HCL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon, Service de Pneumologie et Réanimation, Centre de reference de l'hypertension artérielle pulmonaire, Hôpital Antoine Béclère, Assistance Publique - Hôpitaux de Paris (AP-HP), Université Paris Sud (Paris 11), Hôpital Larrey, Service de Pneumologie, Centre Hospitalier Universitaire de Toulouse, Hôpital Bichat - Claude Bernard, Assistance Publique - Hôpitaux de Paris (AP-HP), Groupe de recherches sur les Maladies Orphelines Pulmonaires (GERMOP), European Respiratory Society [ERS TF 2008-08], UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (MGD) Service de pneumologie, Institut National de la Recherche Agronomique (INRA)-École pratique des hautes études (EPHE), and Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Claude Bernard Lyon 1 (UCBL)

Subjects
Male, emphysème pulmonaire, Pulmonary Fibrosis, Cardiac index, 030204 cardiovascular system & hematology, [SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, Pulmonary function testing, 0302 clinical medicine, Pulmonary fibrosis, pulmonary hypertension, disproportionate, Aged, 80 and over, Chronic obstructive pulmonary disease, Respiratory disease, Syndrome, Middle Aged, Combined pulmonary fibrosis and emphysema, Tobacco smoking, 3. Good health, Survival Rate, medicine.anatomical_structure, emphysema, Pulmonary Emphysema, Cardiology, Female, Pulmonary and Respiratory Medicine, medicine.medical_specialty, fibrose pulmonaire, Hypertension, Pulmonary, Pulmonary hypertension, chronic obstructive pulmonary disease, 03 medical and health sciences, Internal medicine, medicine.artery, medicine, hypertension pulmonaire, Humans, tabagisme, tobacco smoking, Aged, Retrospective Studies, Emphysema, Disproportionate, business.industry, Hemodynamics, medicine.disease, Surgery, 030228 respiratory system, Pulmonary artery, Vascular resistance, business, taux de survie
Abstract

This study aims to describe the haemodynamic and survival characteristics of patients with pulmonary hypertension in the recently individualised syndrome of combined pulmonary fibrosis and emphysema. A retrospective multicentre study was conducted in 40 patients (38 males; age 68±9 yrs; 39 smokers) with combined pulmonary fibrosis and emphysema, and pulmonary hypertension at right heart catheterisation. Dyspnoea was functional class II in 15%, III in 55% and IV in 30%. 6-min walk distance was 244±126 m. Forced vital capacity was 86±18%, forced expiratory volume in 1 s 78±19%, and carbon monoxide diffusion transfer coefficient 28±16% of predicted. Room air arterial oxygen tension was 7.5±1.6 kPa (56±12 mmHg). Mean pulmonary artery pressure was 40±9 mmHg, cardiac index 2.5±0.7 L·min -1·m -2 and pulmonary vascular resistance 521±205 dyn·s·cm -5. 1-yr survival was 60%. Higher pulmonary vascular resistance, higher heart rate, lower cardiac index and lower carbon monoxide diffusion transfer were associated with shorter survival. Patients with combined pulmonary fibrosis and emphysema syndrome and pulmonary hypertension confirmed by right heart catheterisation have a dismal prognosis despite moderately altered lung volumes and flows and moderately severe haemodynamic parameters. Copyright©ERS Journals Ltd 2010.

Published
2009

26. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial

Author

King TE Jr, Albera, C, Bradford, Wz, Costabel, U, Hormel, P, Lancaster, L, Noble, Pw, Sahn, Sa, Szwarcberg, J, Thomeer, M, Valeyre, D, du Bois RM, INSPIRE Study Group, Agostini, Carlo, Allen, J, Anzueto, A, Behr, J, Bonnet, R, Buhl, R, Burge, S, Chan, A, Chan, C, Chanez, P, Chapman, J, Cordier, J, Covelli, H, Crimi, N, de Andrade, J, Delaval, P, Dromer, C, Egan, J, Enelow, R, Ettinger, N, Flaherty, K, Floreani, A, Frankel, S, Frost, A, Gibson, K, Glassberg, M, Gottfried, M, Harari, S, Helmersen, D, Hollingsworth, H, Horton, M, Jennings, J, Kallay, M, Lasky, J, Lee, A, Leonard, C, Lorch, D, Lynch, J, Mageto, Y, Mette, S, Millar, A, Morell Brotad, F, Müller Quernheim, J, Nathan, S, Noth, I, Padilla, M, Poletti, V, Raghu, G, Richeldi, L, Robbins, M, Rolf, J, Roman, J, Rosen, G, Rottoli, P, Saltini, C, Schaberg, T, Schaumberg, T, Scholand, M, Schönfeld, N, Sharma, S, Simonelli, P, Steele, M, Sussman, R, Tino, G, Vogelmeier, C, Wallaert, B, Wells, A, Wencel, M, Wesselius, L, Whelan, T, Wilcox, P, Wolters, P, Xaubet, A, and Zisman, D.

Subjects
Male, medicine.medical_specialty, Settore MED/10 - Malattie dell'Apparato Respiratorio, Injections, Subcutaneous, Vital Capacity, Placebo-controlled study, Kaplan-Meier Estimate, Placebo, Severity of Illness Index, Drug Administration Schedule, Pulmonary function testing, Injections, Idiopathic pulmonary fibrosis, Interferon-gamma, Double-Blind Method, Internal medicine, Pulmonary fibrosis, medicine, Humans, Aged, Analysis of Variance, Disease Progression, Europe, Exercise Test, Female, Idiopathic Pulmonary Fibrosis, North America, Proportional Hazards Models, Pulmonary Diffusing Capacity, Recombinant Proteins, Survival Rate, Treatment Failure, Medicine (all), Survival rate, business.industry, Subcutaneous, Hazard ratio, General Medicine, Interim analysis, medicine.disease, Surgery, business
Abstract

Summary Background Idiopathic pulmonary fibrosis is a fatal disease for which no effective treatment exists. We assessed whether treatment with interferon gamma-1b improved survival compared with placebo in patients with idiopathic pulmonary fibrosis and mild-to-moderate impairment of pulmonary function. Methods 826 patients with idiopathic pulmonary fibrosis were enrolled from 81 centres in seven European countries, the USA, and Canada. Patients were randomly assigned (double-blind) in a 2:1 ratio to receive 200 μg interferon gamma-1b (n=551) or equivalent placebo (n=275) subcutaneously, three times per week. Eligible patients were aged 40–79 years, had been diagnosed in the past 48 months, had a forced vital capacity of 55–90% of the predicted value, and a haemoglobin-corrected carbon monoxide diffusing capacity of 35–90% of the predicted value. The primary endpoint was overall survival time from randomisation measured at the second interim analysis, when the proportion of deaths had reached 75% of those expected by the study conclusion. This study is registered with ClinicalTrials.gov, number NCT00075998. Findings At the second interim analysis, the hazard ratio for mortality in patients on interferon gamma-1b showed absence of minimum benefit compared with placebo (1·15, 95% CI 0·77–1·71, p=0·497), and indicated that the study should be stopped. After a median duration of 64 weeks (IQR 41–84) on treatment, 80 (15%) patients on interferon gamma-1b and 35 (13%) on placebo had died. Almost all patients reported at least one adverse event, and more patients on interferon gamma-1b group had constitutional signs and symptoms (influenza-like illness, fatigue, fever, and chills) than did those on placebo. Occurrence of serious adverse events (eg, pneumonia, respiratory failure) was similar for both treatment groups. Treatment adherence was good and few patients discontinued treatment prematurely in either group. Interpretation We cannot recommend treatment with interferon gamma-1b since the drug did not improve survival for patients with idiopathic pulmonary fibrosis, which refutes previous findings from subgroup analyses of survival in studies of patients with mild-to-moderate physiological impairment of pulmonary function. Funding InterMune.

Published
2009

27. Characterisation of severe obliterative bronchiolitis in rheumatoid arthritis

Author

Devouassoux, G., Cottin, V., Lioté, H., Marchand, Eric, Frachon, I., Schuller, A., Béjui-Thivolet, F., Cordier, J-F., Groupe d'Etudes et de Recherche sur les Maladies \\'Orphelines\\' Pulmonaires (GERM\\'O\\'P), UCL - MD/MINT - Département de médecine interne, UCL - (MGD) Service de pneumologie, Service de pneumologie [Centre Hospitalier Lyon Sud - HCL], Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Centre de référence des maladies rares de l'adulte (CRMRA), Hospices Civils de Lyon (HCL), CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Cliniques Universitaires UCL (UCL), Cliniques Universitaires UCL de Mont-Godinne, Département de Médecine Interne et Pneumologie [Brest] (DMIP - Brest), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Groupe d'Etude de la Thrombose de Bretagne Occidentale (GETBO), Institut Brestois Santé Agro Matière (IBSAM), and Université de Brest (UBO)-Université de Brest (UBO)-Université de Brest (UBO)

Subjects
AIRFLOW OBSTRUCTION, rheumatoid arthritis, Male, Vital capacity, BRONCHIECTASIS, MESH: Chi-Square Distribution, bronchiectasis, [SDV]Life Sciences [q-bio], Biopsy, Vital Capacity, EMPHYSEMA, Gastroenterology, Bronchoalveolar Lavage, Severity of Illness Index, OBLITERATIVE BRONCHIOLITIS, Pulmonary function testing, Arthritis, Rheumatoid, MESH: Biopsy, 0302 clinical medicine, Forced Expiratory Volume, MESH: Thoracoscopy, Bronchiolitis Obliterans, MESH: Aged, MESH: Arthritis, Rheumatoid, MESH: Middle Aged, MESH: Bronchoalveolar Lavage, small airways disease, Respiratory disease, respiratory system, Middle Aged, 3. Good health, emphysema, Echocardiography, Female, Radiography, Thoracic, medicine.symptom, MESH: Tomography, X-Ray Computed, Pulmonary and Respiratory Medicine, Adult, medicine.medical_specialty, obliterative bronchiolitis, MESH: Forced Expiratory Volume, Bronchorrhea, 03 medical and health sciences, FEV1/FVC ratio, MESH: Bronchiolitis Obliterans, Internal medicine, MESH: Severity of Illness Index, medicine, Airflow obstruction, Humans, RHEUMATOID ARTHRITIS, Aged, Retrospective Studies, 030203 arthritis & rheumatology, Bronchiectasis, MESH: Humans, Chi-Square Distribution, business.industry, SMALL AIRWAYS DISEASE, Thoracoscopy, Total Lung Capacity, MESH: Adult, MESH: Retrospective Studies, MESH: Radiography, Thoracic, MESH: Vital Capacity, medicine.disease, MESH: Male, Surgery, respiratory tract diseases, 030228 respiratory system, Respiratory failure, Bronchiolitis, MESH: Echocardiography, business, Tomography, X-Ray Computed, MESH: Female, MESH: Total Lung Capacity
Abstract

International audience; The characteristics of patients with rheumatoid arthritis (RA) who develop obliterative bronchiolitis characterised by severe airflow obstruction have been hitherto poorly investigated. A retrospective study of 25 patients with RA and functional evidence of obliterative bronchiolitis (forced expiratory volume in one second (FEV(1))/forced vital capacity (FVC) 140% predicted) was conducted. Patients (mean+/-SD age 64+/-11 yrs) included 17 never-smokers and eight ex-smokers (10.5+/-5.4 pack-yrs). The diagnosis of RA preceded respiratory symptoms in 88% of cases. Dyspnoea on exertion was present in all patients and bronchorrhea in 44%. High-resolution computed tomography findings included: bronchial wall thickening (96%), bronchiectasis (40%), mosaic pattern (40%), centrilobular emphysema (56%), and reticular and/or ground-glass opacities (32%). Pulmonary function tests showed: FEV(1) 41+/-12% pred, FEV(1)/FVC 49+/-14%, FVC 70+/-20% pred, RV 148+/-68% pred and RV/TLC 142+/-34% pred. Lung biopsy, available in nine patients, demonstrated constrictive, follicular and mixed bronchiolitis. Patients were followed for 48.2+/-49 months. Treatment was poorly effective. Chronic respiratory failure occurred in 40% of patients, and four patients died. Obliterative bronchiolitis associated with rheumatoid arthritis is a severe and under-recognised condition leading to respiratory failure and death in a high proportion of patients.

Published
2009

29. L5. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)

Author

Cordier, J, Cottin, V, Guillevin, L, Bel, E, Bottero, P, Dalhoff, K, Humbert, M, Lazor, R, Sinico, R, Sivasothy, P, Wechsler, M, Wechsler, M., SINICO, RENATO ALBERTO, Cordier, J, Cottin, V, Guillevin, L, Bel, E, Bottero, P, Dalhoff, K, Humbert, M, Lazor, R, Sinico, R, Sivasothy, P, Wechsler, M, Wechsler, M., and SINICO, RENATO ALBERTO

Published
2013

30. Organising pneumonia

Author

Cordier, J.

Subjects
Adrenal Cortex Hormones, Cryptogenic Organizing Pneumonia, Review Series, Humans, Prognosis, Tomography, X-Ray Computed
Published
2000

31. Tokamak inspection: the integration of an articulated robotic inspection arm into CEA's Tore Supra constitutes a promising tool for generic applications

Author

Houry, M., Garguilo, L., Bayetti, P., Bruno, V., Cordier, J.-J., Grisolia, Ch, Hatchressian, J.-C., Samaillie, F., Friconneau, J.-P., Keller, D., and Perrot, Y.

Subjects
Robotics industry -- Production processes, Robotics industry, Business, Business, international, Petroleum, energy and mining industries, International Thermonuclear Experimental Reactor -- Production processes
Abstract

Robotic operations are one of the major maintenance challenges for the International Thermonuclear Experimental Reactor (Iter) project, at Cadarache in France, and future fusion reactors. In particular, in-vessel inspection operations [...]

Published
2008

32. Smoking-related interstitial lung disease

Author

Cordier, J-F, Cerri, S, Spagnolo, P, Luppi, F, Richeldi, L, Cerri S, Spagnolo P, Luppi F, Richeldi L, Cordier, J-F, Cerri, S, Spagnolo, P, Luppi, F, Richeldi, L, Cerri S, Spagnolo P, Luppi F, and Richeldi L

Abstract

Cigarette smoking has a clear epidemiological association with lung diseases, characterised by chronic inflammation of both the bronchiolar and the interstitial lung compartments. There are several different smoking-related interstitial lung diseases, mainly desquamative interstitial pneumonia, respiratory bronchiolitis-associated interstitial lung disease and pulmonary Langerhans' cell histiocytosis. The epidemiology of such diseases is largely unknown, although the prevalence of cigarette smoking, particularly in low-income developing countries, indicates that smoking-induced interstitial lung disorders represent a high burden of disease worldwide. The role of chest high-resolution computed tomography has become increasingly important in differential diagnosis and follow-up. A new entity, the syndrome of combined pulmonary fibrosis and emphysema, emerged as another important smoking-related lung disorder with a poor prognosis, associated with the high prevalence of pulmonary hypertension. At the moment the role of anti-inflammatory and immunosuppressive treatment remains unclear, although in clinical practice most of these patients will receive at least one course of corticosteroid therapy. It is vital to stress the importance of identifying these patients and helping them quit smoking.

Published
2011

33. Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome

Author

UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (MGD) Service de pneumologie, Cottin, V., Le Pavec, J., Prévot, G., Mal, H., Humbert, M., Simonneau, G., Cordier, J.-F., Berezné, A., Coëtmeur, D., Danner-Boucher, I., Funke, D., Israel-Biet, D., Marchand, Eric, Mouthon, L., UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (MGD) Service de pneumologie, Cottin, V., Le Pavec, J., Prévot, G., Mal, H., Humbert, M., Simonneau, G., Cordier, J.-F., Berezné, A., Coëtmeur, D., Danner-Boucher, I., Funke, D., Israel-Biet, D., Marchand, Eric, and Mouthon, L.

Abstract

This study aims to describe the haemodynamic and survival characteristics of patients with pulmonary hypertension in the recently individualised syndrome of combined pulmonary fibrosis and emphysema. A retrospective multicentre study was conducted in 40 patients (38 males; age 68±9 yrs; 39 smokers) with combined pulmonary fibrosis and emphysema, and pulmonary hypertension at right heart catheterisation. Dyspnoea was functional class II in 15%, III in 55% and IV in 30%. 6-min walk distance was 244±126 m. Forced vital capacity was 86±18%, forced expiratory volume in 1 s 78±19%, and carbon monoxide diffusion transfer coefficient 28±16% of predicted. Room air arterial oxygen tension was 7.5±1.6 kPa (56±12 mmHg). Mean pulmonary artery pressure was 40±9 mmHg, cardiac index 2.5±0.7 L·min -1·m -2 and pulmonary vascular resistance 521±205 dyn·s·cm -5. 1-yr survival was 60%. Higher pulmonary vascular resistance, higher heart rate, lower cardiac index and lower carbon monoxide diffusion transfer were associated with shorter survival. Patients with combined pulmonary fibrosis and emphysema syndrome and pulmonary hypertension confirmed by right heart catheterisation have a dismal prognosis despite moderately altered lung volumes and flows and moderately severe haemodynamic parameters. Copyright©ERS Journals Ltd 2010.

Published
2010

34. Characterisation of severe obliterative bronchiolitis in rheumatoid arthritis

Author

UCL - MD/MINT - Département de médecine interne, UCL - (MGD) Service de pneumologie, Devouassoux, G., Cottin, V., Lioté, H., Marchand, Eric, Frachon, I., Schuller, A., Béjui-Thivolet, F., Cordier, J-F., Groupe d'Etudes et de Recherche sur les Maladies "Orphelines" Pulmonaires (GERM"O"P), UCL - MD/MINT - Département de médecine interne, UCL - (MGD) Service de pneumologie, Devouassoux, G., Cottin, V., Lioté, H., Marchand, Eric, Frachon, I., Schuller, A., Béjui-Thivolet, F., Cordier, J-F., and Groupe d'Etudes et de Recherche sur les Maladies "Orphelines" Pulmonaires (GERM"O"P)

Abstract

The characteristics of patients with rheumatoid arthritis (RA) who develop obliterative bronchiolitis characterised by severe airflow obstruction have been hitherto poorly investigated. A retrospective study of 25 patients with RA and functional evidence of obliterative bronchiolitis (forced expiratory volume in one second (FEV1)/forced vital capacity (FVC) <50% and/or residual volume (RV)/total lung capacity (TLC) > 140% predicted) was conducted. Patients (mean +/- SD age 64 +/- 11 yrs) included 17 never-smokers and eight ex-smokers (10.5 +/- 5.4 pack-yrs). The diagnosis of RA preceded respiratory symptoms in 88% of cases. Dyspnoea on exertion was present in all patients and bronchorrhea in 44%. High-resolution computed tomography findings included: bronchial wall thickening (96%), bronchiectasis (40%), mosaic pattern (40%), centrilobular emphysema (56%), and reticular and/or ground-glass opacities (32%). Pulmonary function tests showed: FEV1 41 +/- 12% pred, FEV1/FVC 49 +/- 14%, FVC 70 +/- 20% pred, RV 148 +/- 68% pred and RV/TLC 142 +/- 34% pred. Lung biopsy, available in nine patients, demonstrated constrictive, follicular and mixed bronchiolitis. Patients were followed for 48.2 +/- 49 months. Treatment was poorly effective. Chronic respiratory failure occurred in 40% of patients, and four patients died. Obliterative bronchiolitis associated with rheumatoid arthritis is a severe and under-recognised condition leading to respiratory failure and death in a high proportion of patients.

Published
2009

39. Lipoprotéinose alvéolaire pulmonaire.

Author

UCL - MD/MINT - Département de médecine interne, UCL - (MGD) Service de pneumologie, Briens, E, Delaval, Ph, Mairesse, M P, Valeyre, D, Wallaert, B, Lazor, R, Cordier, J-F, Groupe d'études et de recherche sur les maladies orphelines pulmonaires, Marchand, Eric, UCL - MD/MINT - Département de médecine interne, UCL - (MGD) Service de pneumologie, Briens, E, Delaval, Ph, Mairesse, M P, Valeyre, D, Wallaert, B, Lazor, R, Cordier, J-F, Groupe d'études et de recherche sur les maladies orphelines pulmonaires, and Marchand, Eric

Abstract

[Pulmonary alveolar proteinosis]. Pulmonary alveolar proteinosis (PAP) is a rare, diffuse infiltrative lung disease of unknown etiology characterized by accumulation of abnormal lung surfactant in the alveoli and distal airways. Although it was first described in 1958, few large scale studies have been published. The diagnosis is conventionally based on lung biopsy and the value of less invasive procedures such as bronchoalveolar lavage (BAL) remains controversial. A multi-center retrospective study was conducted in an attempt to update epidemiological, clinical and long term outcome and to assess the usefulness of chest CT scan and BAL in the management of a large homogeneous series of 41 patients. Inclusion criteria required a clinical picture compatible with PAP and either histological confirmation, or a BAL with a milky macroscopic appearance coupled with positive staining to PAS. Mean age was 48.8 years with a 4: 1 male predominance. The prevalence of smokers (80%) and occupational exposure to various inhaled dusts (39%) was high. The clinical, roentgenographic and functional features were in keeping with previous series. Worsening dyspnea was the most common symptom. Other common manifestations were dry cough, recurrent lung infections, weight loss, finger clubbing, crackles and cyanosis. LDH serum levels were increased in 51% of cases. Lung function tests usually showed a mild restrictive ventilatory defect with hypoxemia and reduced DLCO. Chest X ray revealed bilateral ground glass opacities with consolidation or air bronchogram involving peri-hilar or lower lobes. Chest CT scan, performed in 38 patients, revealed a similar pattern in most of them with diffuse intra-alveolar ground glass opacities (33/38) and interlobular thickening (35/38), resulting in a crazy paving appearance in the typical geographic pattern (32/38). This latter aspect was highly suggestive of the diagnosis. Segmental BAL led to a definitive diagnosis in 62% and lung biopsy was only req

Published
2002

43. To the Editors

Author

Cottin, V., primary, Khouatra, C., additional, Lazor, R., additional, Canu, P., additional, and Cordier, J-F., additional

Published
2008
Full Text
View/download PDF

50. Idiopathic chronic eosinophilic pneumonia: A clinical and follow-up study of 62 cases

Author

UCL - MD/MINT - Département de médecine interne, Marchand, Eric, Reynaud-Gaubert, M., Lauque, D., Durieu, J., Tonnel, A.-B., Cordier, J.-F., Brun, J., Brune, J., Mornex, J.F., UCL - MD/MINT - Département de médecine interne, Marchand, Eric, Reynaud-Gaubert, M., Lauque, D., Durieu, J., Tonnel, A.-B., Cordier, J.-F., Brun, J., Brune, J., and Mornex, J.F.

Abstract

Idiopathic chronic eosinophilic pneumonia (CEP) is a rare disorder of unknown cause with nonspecific respiratory and systemic symptoms but rather characteristic peripheral alveolar infiltrates on imaging, developing mainly in women and in atopic subjects. The disorder is highly responsive to oral corticosteroid therapy, but relapses are frequent on reducing or stopping treatment. The long-term course of the disease and data regarding outcome, particularly the need for prolonged oral corticosteroid therapy and the development severe asthma, are somewhat contradictory. A multicentric retrospective study was conducted in an attempt to describe better the initial features and, above all, the later course of CEP in a large homogeneous series of 62 stringently selected patients of whom 46 were followed for more than 1 year. The prevalence of smokers was low (6.5%) and about half of our patients (51.6%) had a previous, and often prolonged, history of asthma. The clinical and roentgenographic features were in keeping with previous studies, but we found that computed tomography could disclose ground glass opacities not detected by X-ray, and that migratory infiltrates before treatment were more frequent (25.5%) than reported previously. The bronchoalveolar lavage cellular count always showed a striking eosinophilic pattern, thus allowing distinction between CEP and cryptogenic organizing pneumonia, both syndromes sharing many common clinical and imaging features. About two-thirds of the patients (68%) showed a ventilatory defect in pulmonary function tests, with about one-half of these presenting with an obstructive pattern, sometimes without previous asthma. Along with the submucosal eosinophilic infiltration noted in 2 patients without ventilatory defect, this is strong evidence to confirm that CEP is not only an alveolointerstitial but also an airway disease. The dramatic response to oral corticosteroid therapy was observed in all treated patients. Although only 1 patient

Published
1998

Catalog

Books, media, physical & digital resources
See catalog results